{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Capricor Therapeutics, Inc."},"Symbol":{"label":"Symbol","value":"CAPR"},"Address":{"label":"Address","value":"10865 ROAD TO THE CURE,SUITE 150, SAN DIEGO, California, 92121, United States"},"Phone":{"label":"Phone","value":"858-727-1755"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Capricor Therapeutics, Inc. is a San Diego based biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases. Capricor's lead candidate, CAP-1002, is an allogeneic cardiac-derived cell therapy that is currently in late-stage clinical development for treating Duchenne muscular dystrophy (DMD). Capricor is also developing its exosome technology as a next-generation therapeutic platform. Capricor's proprietary StealthX exosome platform has potential for a broad range of new therapeutic applications in the field of vaccinology as well as targeted oligonucleotide, protein and small molecule therapeutics to treat or prevent a variety of diseases."},"CompanyUrl":{"label":"Company Url","value":"https://www.capricor.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Kristi A. H. Elliott","title":"Chief Scientific Officer"},{"name":"Linda Marb√°n","title":"President, Chief Executive Officer & Director"},{"name":"Mark Awadalla","title":"Vice President-Clinical Operations"},{"name":"Ming Hao Sun","title":"Vice President-Research & Product Development"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}